Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.57 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955451 | 1.00 | PARP1 (0.57) | PARP1MEP1BF10ADRA1DFOLH1 | |
| Pyridine SCHEMBL2326387 | 0.88 | PARP1 (0.46) | PARP1MEP1BF10ADRA1DFOLH1 | |
| SCHEMBL5232156 | 0.85 | PARP1 (0.53) | PARP1MEP1BF10ADRA1DFOLH1 | |
| SCHEMBL17672270 | 0.83 | PLA2G2A (0.59) | PARP1MEP1BF10FOLH1IDH1 | |
| SCHEMBL46680 | 0.82 | FOLH1 (0.66) | MEP1BFOLH1MRGPRX4MEN1KMT2A | |
| SCHEMBL509423 | 0.82 | LOXL2 (0.66) | PARP1MEP1BFOLH1IDH1TSHR | |
| SCHEMBL29364575 | 0.82 | LOXL2 (0.66) | PARP1MEP1BFOLH1IDH1TSHR | |
| SCHEMBL2734990 | 0.82 | PRSS1 (0.66) | PARP1MEP1BF10FOLH1IDH1 | |
| SCHEMBL39676 | 0.82 | TSHR (0.47) | FOLH1TSHRMRGPRX4 | |
| SCHEMBL28410476 | 0.82 | FOLH1 (0.46) | FOLH1TSHRL3MBTL1MRGPRX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| US-12428745-B2 | Method and system for electroplating parts with metal | DIPSOL CHEMICALS CO., LTD. (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| EP-4524295-A2 | METHOD AND SYSTEM FOR ELECTROPLATING ARTICLE WITH METAL | Dipsol Chemicals Co., Ltd. (JP) | 2025-03-19 | — | — | EP | disclosed |
| US-20240392461-A1 | METHOD AND SYSTEM FOR ELECTROPLATING ARTICLE WITH METAL | DIPSOL CHEM (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024115667-A1 | NON PEPTIDERGIC AGONISTS OF OXYTOCIN RECEPTOR | UNIVERSITE DE STRASBOURG (FR) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
| US-20230349063-A1 | Method and System for Electroplating Parts with Metal | DIPSOL CHEMICALS CO., LTD. (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4269663-A1 | METHOD AND SYSTEM FOR ELECTROPLATING ARTICLE WITH METAL | Dipsol Chemicals Co., Ltd. (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1047698-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999036424-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-07-22 | — | — | WO | disclosed |
| US-5332738-A | Imidazolidine antipsychotic agents | NCNEILAB, INC. (US) | 1994-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | PARP1 3238/4885MEP1B 2340/4885F10 4127/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | PARP1 1195/4885MEP1B 1114/4885F10 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.